Aptevo Reports 21% of AML Patients Advance to Stem Cell Transplant After Mipletamig Combination Therapy
Bitget2026/10/26 12:18- Aptevo Therapeutics reported 10 of 47 evaluable frontline acute myeloid leukemia patients, or 21%, advanced to potentially curative stem cell transplantation.
- Patients initially deemed unfit for intensive chemotherapy received mipletamig with venetoclax and azacitidine.
- Transplant recipients included nine RAINIER trial patients and one dose-expansion patient.
- The historical VIALE-A transplant rate with venetoclax and azacitidine alone was 0.7%; differences between trials limit comparisons.
- RAINIER dose optimization is expected to conclude by year-end 2026, with FDA discussions and Phase 2 initiation anticipated in first-half 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin rebounds sharply from oversold levels, briefly surpassing $57,000

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix
According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.
"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."
Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.
Chun purchased 7,186 ETH worth $11.74 million
